With the prevalence of BDNF Val66Met polymorphism and non-motor symptoms, such as cognitive dysfunction (reduced attention and concentration, executive function, emotional recognition, and global cognition) and depression symptoms, in individuals with PD, there is a need for efficacious therapeutic modalities [1,2,3]. The gene discussed is BDNF; the disease is depressive symptom measurement.